Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity.
Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity.
复制标题
常见的乳腺癌辅助疗法不会抑制癌症疫苗诱导的 T 细胞免疫。
DOI：
10.1007/s10549-008-9910-y
复制
发表时间：
2009
影响因子：
3.8
通讯作者：
Disis,MaryL
中科院分区：
文献类型：
--
作者：
Coveler,AndrewL;Goodell,Vivian;Webster,DevonJ;Salazar,LupeG;Fintak,PatriciaA;Childs,JenniferS;Higgins,DoreenM;Disis,MaryL
当肿瘤负荷处于最低水平时，癌症疫苗在辅助治疗中可能具有最大的临床影响潜力。然而，癌症疫苗在佐剂环境中的应用需要将免疫与更标准的细胞毒性或细胞抑制疗法整合。乳腺癌患者的常用辅助治疗，即曲妥珠单抗、双膦酸盐和激素类药物，通常需要在数年内给药，需要这些药物与主动免疫同时给药。我们质疑这些常见的辅助疗法是否会影响患者通过接种疫苗产生肿瘤特异性免疫的能力。对36例受试者的免疫参数进行了评价。我们确定这些辅助疗法对形成HER-2/neu肽特异性免疫应答的能力没有影响（P> 0.1），它们对同时接种疫苗形成的T细胞免疫的程度也没有影响（P> 0.1）。这是第一份报告表明，使用曲妥珠单抗，双膦酸盐和激素治疗与癌症疫苗同时接种对疫苗诱导的免疫力的产生或程度没有影响。
AbstractsCancer vaccines may have the most potential for clinical impact when used in the adjuvant setting when tumor burden is at its lowest. Application of cancer vaccines in the adjuvant setting, however, requires integration of immunization with more standard cytotoxic or cytostatic therapies. Common adjuvant therapies for breast cancer patients, i.e. trastuzumab, bisphosphonates and hormonal agents are often administered over several years requiring concurrent administration of these drugs with active immunization. We questioned whether these common adjuvant therapies would impact a patient’s ability to develop tumor specific immunity with vaccination. Immune parameters from 36 subjects were evaluated. We determined these adjuvant therapies have no impact on the ability to develop an immune response specific for HER-2/neu peptides (P> 0.1) nor do they have an impact on the magnitude of T cell immunity developed with concurrent vaccination (P> 0.1). This is the first report to show that the use of trastuzumab, bisphosphonates and hormonal therapy concurrent with cancer vaccine administration have no impact on either the generation or the magnitude of vaccine induced immunity.